Anzeige
Mehr »
Mittwoch, 29.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0BLFX | ISIN: SE0001137985 | Ticker-Symbol: BTPC
Frankfurt
29.10.25 | 08:12
0,005 Euro
-36,99 % -0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTIVE BIOTECH AB Chart 1 Jahr
5-Tage-Chart
ACTIVE BIOTECH AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0070,00710:24

Aktuelle News zur ACTIVE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.10.Active Biotech AB: Active Biotech announces a fully secured rights issue of approximately SEK 70 million52NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND...
► Artikel lesen
ACTIVE BIOTECH Aktie jetzt für 0€ handeln
21.08.Active Biotech AB: Interim Report Q2 2025143SECOND QUARTER IN BRIEFActive Biotech reported positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye (May 5)Active Biotech announced that a patent...
► Artikel lesen
08.07.Active Biotech AB: Active Biotech provides status update of its development programs207Lund, Sweden - July 8, 2025 -Active Biotech (NASDAQ Stockholm: ACTI) today provided a status update of its development programs with laquinimod in inflammatory eye disorders and tasquinimod with the...
► Artikel lesen
28.05.Active Biotech AB: Annual General Meeting of Active Biotech AB417The Annual General Meeting of Active Biotech was held on May 28, 2025. The following main resolutions were passed.In accordance with the Board of Directors' proposal, it was resolved that no dividend...
► Artikel lesen
21.05.Active Biotech AB: Active Biotech announces patent for tasquinimod in myelofibrosis granted in Europe496Lund, May 21, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has granted the patent application 21749566.2 related to tasquinimod in myelofibrosis...
► Artikel lesen
08.05.Active Biotech AB: Active Biotech Interim Report Q1 2025532FIRST QUARTER IN BRIEFUS Patent Office granted Active Biotech's patent application for laquinimod in eye disorders (January 28)Active Biotech announced that the first patient was enrolled in the European...
► Artikel lesen
05.05.Active Biotech AB: Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye383Daily treatment with laquinimod eye drops resulted in dose related and therapeutically relevant concentrations of laquinimod in both the anterior and posterior parts of the eye.Laquinimod eye drop treatment...
► Artikel lesen
24.02.Active Biotech AB: First patient enrolled in the HO172 clinical study of tasquinimod in myelofibrosis582Lund Sweden, February 24, 2025 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been included in the phase Ib/II clinical study of tasquinimod in patients with myelofibrosis...
► Artikel lesen
13.02.Active Biotech AB: Active Biotech Year End Report 2024451EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in...
► Artikel lesen
28.01.Active Biotech AB: Active Biotech's patent for laquinimod in eye disorders granted in the US467Lund, January 28, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye...
► Artikel lesen
25.11.24Nasdaq Stockholm AB: New last trading day for paid subscription shares (BTA) of Active Biotech rights issue625At the request of Active Biotech, the last trading day in Active Biotech's paid subscription shares will be changed from 2024-11-26 to 2024-12-04. Instrument: Paid subscription shares Short...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1